Breaking News

MMV, Quotient Sciences Initiate Trial for Long-Acting Malaria Preventive

MMV371 is being developed as a single-dose intramuscular injection that could provide up to three months of protection against malaria.

Author Image

By: Charlie Sternberg

Associate Editor

Medicines for Malaria Venture (MMV) and Quotient Sciences have announced the initiation of a Phase 1 clinical trial for MMV371, a long-acting injectable (LAI) preventive compound for malaria. The trial, conducted in healthy volunteers in Nottingham, UK, marks a significant step towards a new tool to combat malaria, particularly in regions with high transmission rates.   MMV371, a derivative of atovaquone, is being developed as a single-dose intramuscular injection that could provide up to thre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters